New drug combo aims to boost CAR-T success in hard-to-treat lymphoma

NCT ID NCT06854159

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug odronextamab before and after standard CAR-T cell therapy can help people with diffuse large B-cell lymphoma that has returned or not responded to prior treatments. About 34 adults who have already tried at least two other therapies will receive odronextamab to help their immune T cells find and kill cancer cells. The goal is to see if this combination leads to more complete remissions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••